文献速递肾移植肾血管病与高血压

SGLT2抑制剂对糖尿病肾移植受者的心脏保护作用:多中心倾向评分匹配研究

Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study.
PubMed 文献 · Kidney Int Rep · 2024-05-25

本研究纳入6家三级医院的750例糖尿病肾移植受者,其中129例(17.2%)使用SGLT2抑制剂。经倾向评分匹配后每组127例,中位随访55.3个月,SGLT2i组主要不良心血管事件(MACE)和心肌梗死发生率显著低于非SGLT2i组,且不增加尿路感染风险。

要点

  • 糖尿病肾移植受者使用SGLT2i与MACE风险降低相关(校正HR 0.30)。
  • SGLT2i组心肌梗死风险显著降低(校正HR 0.04)。
  • 两组尿路感染发生率无差异。

核心结论

  • SGLT2i显著降低糖尿病肾移植受者心血管事件风险,尤其降低心肌梗死和心血管原因死亡发生率。

研究设计与样本

  • 多中心倾向评分匹配研究,纳入6家三级医院750例糖尿病肾移植受者,其中129例(17.2%)使用SGLT2i。

主要发现

  • 匹配队列每组127例,随访55.3个月,SGLT2i组MACE发生5例(3.9%),非SGLT2i组15例(11.8%)。
  • SGLT2i组MACE和心肌梗死发生率均低于非SGLT2i组(P=0.036和0.008)。
  • 多因素分析显示SGLT2i组MACE风险较低(校正HR 0.30,95%CI 0.10-0.88,P=0.028)。
  • SGLT2i组心肌梗死风险较低(校正HR 0.04,95%CI 0.004-0.40,P=0.006)。
  • 两组尿路感染发生率无差异。

临床怎么用

  • 对于糖尿病肾移植受者,可考虑使用SGLT2i以降低心血管事件负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Kidney transplantation (KT) improves the cardiovascular outcomes of patients with end-stage kidney disease. However, cardiovascular disease remains the leading cause of premature death and graft loss in KT recipients (KTRs) with diabetes. We evaluated the cardioprotective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in KTRs with diabetes. METHODS: A total of 750 KTRs with diabetes were enrolled from 6 tertiary hospitals. Among them, 129 patients (17.2%) were prescribed SGLT2i. The primary outcome was the incidence of major adverse cardiovascular events (MACE), which comprised myocardial infarction (MI), death from cardiovascular causes, hospitalization for heart failure, and stroke. Multivariable Cox regression analysis and propensity score matching were used to investigate the effect of SGLT2i on clinical outcomes. RESULTS: In the matched cohort, MACE occurred in 5 patients (3.9%) in the SGLT2i group and 15 patients (11.8%) in the non-SGLT2i group, out of 127 patients in each group over 55.3 months. The incidence of MACE and MI was lower in the SGLT2i group than in the non-SGLT2i group (P = 0.036 and 0.008, respectively). In multivariate analysis, the SGLT2i group had a lower risk of MACE and MI than the non-SGLT2i group (adjusted hazard ratio [HR], 0.30 and 0.04; 95% confidence interval [CI], 0.10-0.88 and 0.004-0.40; P = 0.028 and 0.006, respectively). There was no difference in the incidence of urinary tract infection (UTI) between the 2 groups. CONCLUSION: SGLT2i significantly decreased the risk of cardiovascular events in KTRs with diabetes, particularly lowering the incidence of MI and death from cardiovascular causes. SGLT2i can be used to reduce the burden of cardiovascular disease in KTRs with diabetes.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Lim JH, Kwon S, Seo YJ, et al. Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study. Kidney Int Rep. 2024. PMID: 39156155. doi:10.1016/j.ekir.2024.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。